Back to top
more

Dicerna Pharmaceuticals, Inc. (DRNA)

(Delayed Data from NSDQ)

$13.09 USD

13.09
283,655

+0.43 (3.40%)

Updated May 3, 2019 04:00 PM ET

After-Market: $13.09 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.

    What's in Store for Adverum (ADVM) This Earnings Season?

    On Adverum's (ADVM) second-quarter 2018 conference call, investor focus will be on the company's progress with its pipeline candidates.

      Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher

      Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

        Arpita Dutt headshot

        4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings

        Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.

          Can The Uptrend Continue for Dicerna Pharmaceuticals (DRNA)?

          Investors certainly have to be happy with Dicerna Pharmaceuticals, Inc. (DRNA) and its short term performance

            Dicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14%

            Dicerna Pharmaceuticals, Inc. (DRNA) shares rose over 14% in the last trading session.

              Cerner's EHR Platform to Enhance Health Care at San Juan NGO

              Cerner Corporation (CERN) announced that it recently entered into an agreement to provide San Juan Regional Medical Center with a new electronic health record platform.

                Stocks Most Likely to Beat Earnings for the week of February 13th

                Here are four Zacks Rank #1 (Strong Buy) stocks that are likely to beat earnings for the week of February 13th:

                  Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%

                  Kindred Biosciences, Inc. (KIN) shares rose over 9% in the last trading session.

                    Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session

                    Array BioPharma Inc. (ARRY) shares rose over 7% in the last trading session.